| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
3 companies
Robert Ross Carter is Chief Financial Officer at TOIIW and has filed Form 4s across 3 companies. Robert Ross Carter's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.7M at current prices.
The biggest single holding is STLN (~$2.6M) as Chief Financial Officer.
Robert Ross Carter has 11 Form 4 filings on record from November 2024 to May 2026, across 3 companies: Chief Financial Officer at Starling Oncology (STLN), 2026; Chief Financial Officer at The Oncology Institute (TOIIW), 2026; Chief Financial Officer at Oncology Institute (TOI), 2024–2026.
The 13 reported transactions were 4 dispositions back to the company, 3 other transactions, 3 stock awards and 2 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $9K and 1 sale worth about $879.
The only open-market purchase was 9,056 shares of TOI at an average $1.04 on March 26, 2025, about $9K. Twelve months later TOI was up 156%.
The only open-market sale was 247 shares of TOI at an average $3.56 on January 2, 2026, about $879.